The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability
Open accessAbstract
Individuals with hemizygous germline fumarate hydratase (FH) mutations are predisposed to renal cancer. These tumors predominantly exhibit functional inactivation of the remaining wild-type allele, implicating FH inactivation as a tumor-promoting event. Hypoxia-inducible factors are expressed in many cancers and are increased in clear cell renal carcinomas. Under normoxia, the HIFs are labile due to VHL-dependent proteasomal degradation, but stabilization occurs under hypoxia due to inactivation of HIF prolyl hydroxylase (HPH), which prevents HIF hydroxylation and VHL recognition. We demonstrate that FH inhibition, together with elevated intracellular fumarate, coincides with HIF upregulation. Further, we show that fumarate acts as a competitive inhibitor of HPH. These data delineate a novel fumarate-dependent pathway for regulating HPH activity and HIF protein levels.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to requiring 2-oxoglutarate as a cosubstrate, the HIF hydroxylases have been reported to be inhibited by citrate, isocitrate, succinate, fumarate, malate, oxaloacetate, and pyruvate (Dalgard et al., 2004; Hewitson et al., 2007; Isaacs et al., 2005; Koivunen et al., 2007a; Selak et al., 2005).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Isaacs et al., 2005
In the citing paper
“To date, the clearest evidence that metabolites modulate HIF signaling comes from cells that are genetically defective in fumarate hydratase (FH) (Isaacs et al., 2005) or succinate hydrogenase (SDH; subunits b, c, and d) (MacKenzie et al., 2007; Pollard et al., 2005; Selak et al., 2005).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Isaacs et al., 2005
In the citing paper
“Similar to succinate, fumarate contributes to the inactivation of PHD, stabilizing HIF proteins to promote cell survival133”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [133]
In the citing paper
“For example, the HIF1α transcription factor accumulates in SDH and FH mutant tumors, presumably due to inhibition of the EglN prolyl hydroxylases (Dahia et al., 2005; Isaacs et al., 2005; Pollard et al., 2005, 2007; Selak et al., 2005).”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Isaacs et al., 2005
In the citing paper
“A similar model of substrate-mediated PHD inhibition has been described (23, 37, 42) in which the loss of fumarate hydratase activity leads to the accumulation of fumarate, which also can inhibit PHD competitively.”
From Loss of the SdhB, but Not the SdhA, Subunit of Complex II Triggers Reactive Oxygen Species-Dependent Hypoxia-Inducible Factor Activation and Tumorigenesis (2008) · cites this paper as [23]
In the citing paper
“PHDs are inactive at low O2 and can be inactivated by the accumulation of TCA metabolites fumarate and succinate, which may occur from mutations in the tumor suppressor genes succinate dehydrogenase subunit B or fumarate hydratase (187, 334, 384).”
From Redox regulation of mitochondrial function (2012) · cites this paper as [187]
In the citing paper
“In addition to affecting the activity of chromatin-associated αKG-dependent dioxygenases, succinate and fumarate accumulation can also inhibit αKG-dependent prolyl hydroxylases, leading to stabilization of HIF-1 and concomitant activation of the HIF/hypoxia transcriptional program (184, 185).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [184]
In the citing paper
“High levels of succinate and fumarate can inhibit PHD2 activity through product-mediated inhibition of PHD function, leading to HIF-1α protein stabilization under normoxic (20% O2) conditions (100, 101).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [100]
In the citing paper
“Subsequent work confirmed that fumarate could inhibit PHD2 (Isaacs et al., 2005)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Isaacs et al., 2005
In the citing paper
“elevated levels of succinate or fumarate can inhibit PHD activity [65, 66]”
From Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function (2013) · cites this paper as [65]
In the citing paper
“Both succinate and fumarate are competitive PHD inhibitors, and the massive accumulation of these metabolites in cells lacking SDH or FH activity elicit a hypoxic response even under oxygen-replete condition (Isaacs et al., 2005; Selak et al., 2005).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Isaacs et al., 2005
In the citing paper
“Furthermore, both succinate and fumarate aberrantly increase the function of hypoxia inducible factors (HIFs).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Isaacs et al., 2005
In the citing paper
“In the case of D2HGA, about 50% of patients present with D2HGDH mutations, while the remaining half possess mutations in the Krebs cycle enzyme isocitrate dehydrogenase 2 (IDH2), which converts isocitrate to α-KG110.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [110]
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
Self-citationThe tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Self-citationHIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Self-citationA conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Cellular and developmental control of O 2 homeostasis by hypoxia-inducible factor 1α
Iyer, N. V., Kotch, L. E., Agani, F., Leung, S. W., Laughner, E., Wenger, R. H., Gassmann, M., Gearhart, J. D., Lawler, A. M., Yu, A. Y., et al. (1998) · Genes & Development · doi:10.1101/gad.12.2.149 · Cited by 2,476
(1999) · PubMed · Cited by 2,204
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108 · cited 3×
“Succinate also upregulates HIF by inhibiting its proline hydroxylation (Selak et al., 2005), but in vitro enzyme kinetic analysis proves it to be a weaker antagonist of 2-OG, a finding in keeping with its reduced potency (relative to fumarate) in causing intracellular HIF accumulation in A549 cells.”
BackgroundInfluential
Flagged first, then by citations
1 of the 63 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 957
The Warburg effect: Insights from the past decade
Upadhyay, M., Samal, J., Kandpal, M., Singh, O. V., & Vivekanandan, P. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.11.003 · Cited by 252
The Mammalian Target of Rapamycin Signaling Pathway: Twists and Turns in the Road to Cancer Therapy
Abraham, R. T., & Gibbons, J. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2798 · Cited by 244
Genetic basis of kidney cancer: Role of genomics for the development of disease-based therapeuticsPreprint
Linehan, W. M. (2012) · Genome Research · doi:10.1101/gr.131110.111 · Cited by 243
Self-citationSmeitink, J. A. M., Zeviani, M., Turnbull, D. M., & Jacobs, H. T. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2005.12.001 · Cited by 251
Li, F., He, X., Ye, D., Lin, Y., Yu, H., Yao, C., Huang, L., Zhang, J., Wang, F., Xu, S., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.017 · Cited by 244
Protein Lysine Acylation and Cysteine Succination by Intermediates of Energy Metabolism
Lin, H., Su, X., & He, B. (2012) · ACS Chemical Biology · doi:10.1021/cb3001793 · Cited by 238
Hewitson, K. S., Liénard, B. M. R., McDonough, M. A., Clifton, I. J., Butler, D., Soares, A. S., Oldham, N. J., McNeill, L. A., & Schofield, C. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608337200 · Cited by 235
McNamee, E. N., Korns Johnson, D., Homann, D., & Clambey, E. T. (2013) · Immunologic Research · doi:10.1007/s12026-012-8349-8 · Cited by 234
Regulating cellular oxygen sensing by hydroxylation
Fandrey, J., Gorr, T. A., & Gassmann, M. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.05.005 · Cited by 234
Xie, H., Valera, V., Merino, M. J., Amato, A. M., Signoretti, S., Linehan, W. M., Sukhatme, V. P., & Seth, P. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1049 · Cited by 233
Self-citation2-Oxoglutarate-dependent dioxygenases in cancer
Losman, J.-A., Koivunen, P., & Kaelin, W. G. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-00303-3 · Cited by 241
Vazquez, A., Kamphorst, J. J., Markert, E. K., Schug, Z. T., Tardito, S., & Gottlieb, E. (2016) · Journal of Cell Science · doi:10.1242/jcs.181016 · Cited by 225
Metabolic transformation in cancer
Tennant, D. A., Durán, R. V., Boulahbel, H., & Gottlieb, E. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp070 · Cited by 235
Regulatory mechanisms of hypoxia‐inducible factor 1 activity: Two decades of knowledge
Koyasu, S., Kobayashi, M., Gotö, Y., Hiraoka, M., & Harada, H. (2017) · Cancer Science · doi:10.1111/cas.13483 · Cited by 233
mTORC1 as a Regulator of Mitochondrial Functions and a Therapeutic Target in Cancer
de la Cruz-López, K. G., Toledo-Guzmán, M. E., Sánchez, E. O., & Carrancá, A. G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01373 · Cited by 223
Linehan, W. M., & Rouault, T. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0304 · Cited by 226
Self-citationZdzisińska, B., Żurek, A., & Kandefer-Szerszeń, M. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-016-0406-x · Cited by 221
Payen, V. L., Porporato, P. E., Baselet, B., & Sonveaux, P. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2098-5 · Cited by 226
Yogev, O., Yogev, O., Singer, E., Shaulian, E., Goldberg, M., Fox, T. D., & Pines, O. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000328 · Cited by 220
Ebbesen, P., Pettersen, E. O., Gorr, T. A., Jobst, G., Williams, K. J., Kieninger, J., Wenger, R. H., Pastoreková, S., Dubois, L. J., Lambin, P., et al. (2009) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756360902784425 · Cited by 221
Self-citationHypoxia-dependent regulation of inflammatory pathways in immune cells
Taylor, C. T., Doherty, G. A., Fallon, P. G., & Cummins, E. P. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84433 · Cited by 224
Oncometabolites in renal cancer
Yong, C., Stewart, G. D., & Frezza, C. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0210-z · Cited by 216
Sudarshan, S., Sourbier, C., Kong, H.-S., Block, K., Romero, V. A. V., Yang, Y., Galindo, C., Mollapour, M., Scroggins, B., Goode, N., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00483-09 · Cited by 217
Self-citationNon-heme dioxygenases: cellular sensors and regulators jelly rolled into one?
Ozer, A., & Bruick, R. K. (2007) · Nature Chemical Biology · doi:10.1038/nchembio863 · Cited by 214
Tong, W.-H., Sourbier, C., Kovtunovych, G., Jeong, S. Y., Vira, M., Ghosh, M., Romero, V. V., Sougrat, R., Vaulont, S., Viollet, B., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.07.018 · Cited by 212
Self-citationHereditary Kidney Cancer Syndromes
Haas, N. B., & Nathanson, K. L. (2013) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2013.10.001 · Cited by 221
How does cancer cell metabolism affect tumor migration and invasion?
Han, T., Kang, D., Ji, D., Wang, X., Zhan, W., Fu, M., Xin, H.-B., & Wang, J.-B. (2013) · Cell Adhesion & Migration · doi:10.4161/cam.26345 · Cited by 198
You, Y.-H., Quach, T., Saito, R., Pham, J., & Sharma, K. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015030302 · Cited by 191
The emerging role of fumarate as an oncometabolite
Yang, M., Soga, T., Pollard, P. J., & Adam, J. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00085 · Cited by 189
Reactive oxygen species and cellular oxygen sensing
Cash, T. P., Pan, Y., & Simon, M. C. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.07.001 · Cited by 195
Abnormal Sympathoadrenal Development and Systemic Hypotension in PHD3−/− Mice
Bishop, T., Gallagher, D., Pascual, A., Lygate, C. A., de Bono, J. P., Nicholls, L. G., Ortega‐Sáenz, P., Oster, H., Wijeyekoon, B., Sutherland, A., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.02041-07 · Cited by 186
Self-citationŁoboda, A., Józkowicz, A., & Dulak, J. (2015) · Vascular Pharmacology · doi:10.1016/j.vph.2015.09.004 · Cited by 186
Hong, S., Oh, H., Valera, V., Baba, M., Schmidt, L. S., & Linehan, W. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015793 · Cited by 183
Self-citationMetabolic Signaling to the Nucleus in Cancer
Campbell, S. L., & Wellen, K. E. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.07.015 · Cited by 186
Shin, D., Lee, J., You, J. H., Kim, D., & Roh, J. (2020) · Redox Biology · doi:10.1016/j.redox.2019.101418 · Cited by 179
Oncometabolites: Unconventional triggers of oncogenic signalling cascades
Sciacovelli, M., & Frezza, C. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.04.025 · Cited by 184
Germline FH Mutations Presenting With Pheochromocytoma
Clark, G. R., Sciacovelli, M., Gaude, E., Walsh, D. M., Kirby, G. A., Simpson, M. A., Trembath, R. C., Berg, J. N., Woodward, E. R., Kinning, E., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1659 · Cited by 185
Pollard, P. J., Spencer‐Dene, B., Shukla, D., Howarth, K. M., Nye, E. L., El-Bahrawy, M. A., Deheragoda, M. G., Kolatsi‐Joannou, M., McDonald, S. A. C., Martin, A., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.005 · Cited by 182
Metabolic changes in cancer: beyond the Warburg effect
Wu, W., & Zhao, S. (2013) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gms104 · Cited by 173
Molecular targeting of hypoxia in radiotherapy
Rey, S., Schito, L., Koritzinsky, M., & Wouters, B. G. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.10.002 · Cited by 178
Current Approaches and Recent Developments in the Management of Head and Neck Paragangliomas
Taïeb, D., Kaliski, A., Boedeker, C. C., Martucci, V. L., Fojo, T., Adler, J. R., & Pacák, K. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1026 · Cited by 169
Molecular Diagnosis and Therapy of Kidney Cancer
Linehan, W. M., Bratslavsky, G., Pinto, P. A., Schmidt, L. S., Neckers, L., Bottaro, D. P., & Srinivasan, R. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.042808.171650 · Cited by 167
Self-citationKaluz, Š., Kaluzová, M., & Stanbridge, E. J. (2008) · Clinica Chimica Acta · doi:10.1016/j.cca.2008.05.002 · Cited by 179
Hypoxia‐inducible factor as a physiological regulator
Maxwell, P. H. (2005) · Experimental Physiology · doi:10.1113/expphysiol.2005.030924 · Cited by 170
Fumarate hydratase in cancer: A multifaceted tumour suppressor
Schmidt, C., Sciacovelli, M., & Frezza, C. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.002 · Cited by 166
Bayley, J., Launonen, V., & Tomlinson, I. P. M. (2008) · BMC Medical Genetics · doi:10.1186/1471-2350-9-20 · Cited by 167
TCA Cycle Defects and Cancer: When Metabolism Tunes Redox State
Cardaci, S., & Ciriolo, M. R. (2012) · International Journal of Cell Biology · doi:10.1155/2012/161837 · Cited by 169
State of the Science: An Update on Renal Cell Carcinoma
Jonasch, E. W., Futreal, P. A., Davis, I. J., Bailey, S. T., Kim, W. Y., Brugarolas, J., Giaccia, A. J., Kurban, G., Pause, A., Frydman, J., et al. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0117 · Cited by 165
Kaelin, W. G. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.010975 · Cited by 161
Genetic predisposition to kidney cancer
Schmidt, L. S., & Linehan, W. M. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.09.001 · Cited by 163
Self-citationThe role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy
Tal, R., & Segars, J. H. (2013) · Human Reproduction Update · doi:10.1093/humupd/dmt042 · Cited by 159
HIF‐prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism
Haase, V. H. (2017) · Hemodialysis International · doi:10.1111/hdi.12567 · Cited by 164
Schultz, K. A. P., Rednam, S. P., Kamihara, J., Doros, L. A., Achatz, M. I., Wasserman, J. D., Diller, L., Brugières, L., Druker, H. A., Schneider, K. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0629 · Cited by 160
Lee, S., & Griffiths, J. R. (2020) · Cancers · doi:10.3390/cancers12061616 · Cited by 163
Self-citationHereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics
Lehtonen, H. J. (2011) · Familial Cancer · doi:10.1007/s10689-011-9428-z · Cited by 156
Hereditary leiomyomatosis and renal cell carcinoma
Schmidt, L. S., & Linehan, W. M. (2014) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s42097 · Cited by 158
Self-citationLin, C.-C., Cheng, T., Tsai, W., Tsai, H.-J., Hu, K.-H., Chang, H., Yeh, C., Chen, Y.-C., Liao, C.-C., & Chang, W. (2012) · Scientific Reports · doi:10.1038/srep00785 · Cited by 163
HYPOXIA‐INDUCED ERYTHROPOIETIN PRODUCTION: A PARADIGM FOR OXYGEN‐REGULATED GENE EXPRESSION
Stockmann, C., & Fandrey, J. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04474.x · Cited by 159
Linehan, W. M., Pinto, P. A., Srinivasan, R., Merino, M. J., Choyke, P. L., Choyke, L. T., Coleman, J., Toro, J. R., Glenn, G. M., Vocke, C. D., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1870 · Cited by 151
Self-citationHIF-1 versus HIF-2 — Is one more important than the other?
Loboda, A., Jozkowicz, A., & Dulak, J. (2012) · Vascular Pharmacology · doi:10.1016/j.vph.2012.02.006 · Cited by 152
Isoe, T., Makino, Y., Mizumoto, K., Sakagami, H., Fujita, Y., Honjo, J., Takiyama, Y., Itoh, H., & Haneda, M. (2010) · Kidney International · doi:10.1038/ki.2010.99 · Cited by 152
Oncometabolites‐driven tumorigenesis: From genetics to targeted therapy
Morin, A., Letouzé, É., Gimenez‐Roqueplo, A., & Favier, J. (2014) · International Journal of Cancer · doi:10.1002/ijc.29080 · Cited by 162
Zhao, X.-Y., Chen, T., Li, X., Guo, M., Xu, Y., Yue, F., Jiang, Y., Chen, G., & Zhao, K.-W. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq116 · Cited by 150
Inborn and acquired metabolic defects in cancer
Frezza, C., Pollard, P. J., & Gottlieb, E. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0728-4 · Cited by 147
The metabolic basis of kidney cancer
Linehan, W. M., & Ricketts, C. J. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.06.002 · Cited by 152
Self-citationOncometabolites: tailoring our genes
Nowicki, S., & Gottlieb, E. (2015) · FEBS Journal · doi:10.1111/febs.13295 · Cited by 148
Zacharias, N. M., Chan, H. R., Sailasuta, N., Ross, B. D., & Bhattacharya, P. K. (2011) · Journal of the American Chemical Society · doi:10.1021/ja2040865 · Cited by 144
Gardie, B., Remenieras, A., Kattygnarath, D., Bombled, J., Lefèvre, S.-H., Perrier-Trudova, V., Rustin, P., Barrois, M., Slama, A., Avril, M., et al. (2011) · Journal of Medical Genetics · doi:10.1136/jmg.2010.085068 · Cited by 148
Yang, Y., Valera, V., Padilla‐Nash, H. M., Sourbier, C., Vocke, C. D., Vira, M. A., Abu-Asab, M. S., Bratslavsky, G., Tsokos, M., Merino, M. J., et al. (2009) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2009.08.018 · Cited by 139
Self-citationLactic Acidosis Triggers Starvation Response with Paradoxical Induction of TXNIP through MondoA
Chen, J. L.-Y., Merl, D., Peterson, C. W., Wu, J., Liu, P. Y., Yin, H., Muoio, D. M., Ayer, D. E., West, M., & Chi, J. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001093 · Cited by 136
Macrophage metabolic reprogramming aggravates aortic dissection through the HIF1α-ADAM17 pathway✰
Lian, G., Li, X., Zhang, L., Zhang, Y., Sun, L., Zhang, X., Liu, H., Pang, Y., Kong, W., Zhang, T., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.09.041 · Cited by 139
Cancer metabolism and tumor microenvironment: fostering each other?
Yuan, Y., Li, H., Wang, P., Chen, L., Guo, D. S., Jiang, H., He, B., Qin, S., Wang, K., Li, N., et al. (2021) · Science China Life Sciences · doi:10.1007/s11427-021-1999-2 · Cited by 140
Hypoxia-Inducible Factor-1: A Critical Player in the Survival Strategy of Stressed Cells
Chen, S., & Sang, N. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25283 · Cited by 137
Sanz‐Ortega, J., Vocke, C. D., Stratton, P., Linehan, W. M., & Merino, M. J. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31825ec16f · Cited by 133
Self-citationGenetics and epigenetics of renal cell cancer
Baldewijns, M. M. L. L., van Vlodrop, I. J. H., Schouten, L. J., Soetekouw, P. M. M. B., de Bruı̈ne, A. P., & van Engeland, M. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.12.002 · Cited by 133
Mitochondrial oxidative phosphorylation TRAP(1)ped in tumor cells
Rasola, A., Neckers, L., & Picard, D. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.03.005 · Cited by 129
Self-citationThe epigenetic landscape of renal cancer
Morris, M. R., & Latif, F. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.168 · Cited by 129
A chemoproteomic portrait of the oncometabolite fumarate
Kulkarni, R. A., Bak, D. W., Wei, D., Bergholtz, S. E., Briney, C. A., Shrimp, J. H., Alpsoy, A., Thorpe, A. L., Bavari, A. E., Crooks, D. R., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-018-0217-y · Cited by 122
Self-citationMitochondrial dynamics regulate genome stability via control of caspase-dependent DNA damage
Cao, K., Riley, J. S., Heilig, R., Montes-Gómez, A. E., Vringer, E., Berthenet, K., Cloix, C., Elmasry, Y., Spiller, D. G., Ichim, G., et al. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.03.019 · Cited by 124
Reactivating HIF prolyl hydroxylases under hypoxia results in metabolic catastrophe and cell death
Tennant, D. A., Frezza, C., MacKenzie, E. D., Nguyen, Q., Zheng, L., Selak, M. A., Roberts, D. L., Dive, C., Watson, D. G., Aboagye, E. O., et al. (2009) · Oncogene · doi:10.1038/onc.2009.250 · Cited by 122
Autophagy, Stress, and Cancer Metabolism: What Doesn't Kill You Makes You StrongerPreprint
Mathew, R., & White, E. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2012.76.011015 · Cited by 131
Liang Cheng, C., Zhang, S., MacLennan, G. T., Antonio Lopez-beltran, B., & Montironi, R. (2008) · Human Pathology · doi:10.1016/j.humpath.2008.09.009 · Cited by 124
Succination of Protein Thiols during Adipocyte Maturation
Nagai, R., Brock, J. W. C., Blatnik, M., Baatz, J. E., Bethard, J. R., Walla, M. D., Thorpe, S. R., Baynes, J., & Frizzell, N. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703551200 · Cited by 122
Alterations of metabolic genes and metabolites in cancer
Oermann, E. K., Wu, J., Guan, K., & Xiong, Y. (2012) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2012.01.013 · Cited by 125
Campbell, S. C., & Lane, B. R. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6911-9.00049-9 · Cited by 122
Mitochondrial dysfunction in cancer: Potential roles of ATF5 and the mitochondrial UPR
Deng, P., & Haynes, C. M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.05.002 · Cited by 121
Siddiq, A., Aminova, L. R., & Ratan, R. R. (2007) · Neurochemical Research · doi:10.1007/s11064-006-9268-7 · Cited by 121
Prolyl 4‐hydroxylases, master regulators of the hypoxia response
Myllyharju, J. (2013) · Acta Physiologica · doi:10.1111/apha.12096 · Cited by 123
Development of novel therapeutic strategies that target HIF-1
Semenza, G. L. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.2.267 · Cited by 120
Kaelin, W. G. (2009) · Cancer · doi:10.1002/cncr.24232 · Cited by 120
Bayley, J., & Devilee, P. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.02.008 · Cited by 119
Genetic alterations in Krebs cycle and its impact on cancer pathogenesis
Sajnani, K., Islam, F., Smith, R. A., Gopalan, V., & Lam, A. K.-Y. (2017) · Biochimie · doi:10.1016/j.biochi.2017.02.008 · Cited by 121
Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights
Carlo, M. I., Hakimi, A. A., Stewart, G. D., Bratslavsky, G., Brugarolas, J., Chen, Y., Linehan, W. M., Maher, E. R., Merino, M. J., Offit, K., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.06.015 · Cited by 125
Self-citationHypoxia, drug therapy and toxicity
Lee, K., Roth, R. A., & LaPres, J. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.08.001 · Cited by 118
Regulated oxygen sensing by protein hydroxylation in renal erythropoietin-producing cells
Wenger, R. H., & Hoogewijs, D. (2010) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00736.2009 · Cited by 120
JmjC enzyme KDM2A is a regulator of rRNA transcription in response to starvation
Tanaka, Y., Okamoto, K., Teye, K., Umata, T., Yamagiwa, N., Suto, Y., Zhang, Y., & Tsuneoka, M. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.56 · Cited by 118
Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers
Chappell, J. C., Payne, L. B., & Rathmell, W. K. (2019) · Journal of Clinical Investigation · doi:10.1172/jci120855 · Cited by 117
Fumarate hydratase (FH) and cancer: a paradigm of oncometabolism
Valcárcel-Jiménez, L., & Frezza, C. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02412-w · Cited by 117
Harada, H. (2016) · Journal of Radiation Research · doi:10.1093/jrr/rrw012 · Cited by 116
Interplay Among Metabolism, Epigenetic Modifications, and Gene Expression in Cancer
Huo, M., Zhang, J., Huang, W., & Wang, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.793428 · Cited by 117
Metadata
- Authors
- Isaacs, J. S., Jung, Y. J., Mole, D. R., Lee, S., Torres-Cabala, C., Chung, Y.-L., Merino, M., Trepel, J., Zbar, B., Toro, J., Ratcliffe, P. J., Linehan, W. M., & Neckers, L.
- Affiliations
- National Institutes of Health (US)
- Pusan National University (KR)
- University of Oxford (GB)
- National Cancer Institute (US)
- St George's Hospital (GB)
- Corresponding author
- Neckers, Len
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2005-08
- Volume
- 8
- Issue
- 2
- Pages
- 143-153
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2059747280
- Semantic Scholar
- 6906ef0c1fe45571640c3c7a6b3c9c2d9a979a64
- Cited by
- 958
- References
- 63
- Citations by year
- 2026: 26 · 2025: 30 · 2024: 30 · 2023: 36 · 2022: 45 · 2021: 37 · 2020: 46 · 2019: 40 · 2018: 50 · 2017: 40 · 2016: 44 · 2015: 64 · 2014: 54 · 2013: 60 · 2012: 64
- FWCI
- 14.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- fumarate hydratase, hypoxia-inducible factor, fumarate, HIF prolyl hydroxylase, competitive inhibition, clear cell renal cell carcinoma, biallelic loss, cancer susceptibility, hypoxia
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Adult, Alleles, Carcinoma, Renal Cell, DNA-Binding Proteins, Female, Fumarate Hydratase, Fumarates, Humans, Ketoglutaric Acids, Kidney Neoplasms, Male, Middle Aged, Nuclear Proteins, Procollagen-Proline Dioxygenase, Syndrome, Transcription Factors, Up-Regulation, Gene Expression Regulation, Neoplastic, Leiomyomatosis, Basic Helix-Loop-Helix Proteins, Basic Helix-Loop-Helix Transcription Factors, Hypoxia-Inducible Factor 1, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
